Real-World Data for the Evaluation of Transarterial Radioembolization versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
Open Access
- 1 March 2017
- journal article
- research article
- Published by Elsevier in Value in Health
- Vol. 20 (3) , 336-344
Abstract
No abstract availableKeywords
This publication has 44 references indexed in Scilit:
- Cost-effectiveness analysis of treatment with peginterferon-alfa-2a versus peginterferon-alfa-2b for patients with chronic hepatitis C under the public payer perspective in BrazilCost Effectiveness and Resource Allocation, 2013
- Cost Effectiveness of Fibrosis Assessment Prior to Treatment for Chronic Hepatitis C PatientsPLOS ONE, 2011
- Which is more cost‐effective under the MELD system: primary liver transplantation, or salvage transplantation after hepatic resection or after loco‐regional therapy for hepatocellular carcinoma within Milan criteria?HPB, 2011
- Management of Hepatocellular Carcinoma: An Update ΔσHepatology, 2011
- Radioembolization Results in Longer Time-to-Progression and Reduced Toxicity Compared With Chemoembolization in Patients With Hepatocellular CarcinomaGastroenterology, 2011
- Cost–Utility Analysis of Tenofovir Disoproxil Fumarate in the Treatment of Chronic Hepatitis BValue in Health, 2010
- Cost-Effectiveness of Nationwide Hepatitis B Catch-Up Vaccination Among Children and Adolescents in ChinaHepatology, 2010
- Use of Sorafenib in Patients With Hepatocellular Carcinoma Before Liver Transplantation: A Cost-Benefit Analysis While Awaiting Data on Sorafenib SafetyHepatology, 2009
- Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studiesLiver International, 2009
- The central role of the propensity score in observational studies for causal effectsBiometrika, 1983